High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
about
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonistEvaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guidelineHigh density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular riskHDL particle number and size as predictors of cardiovascular diseaseCardioprotective functions of HDLsCholesterol and lipoprotein dynamics in a hibernating mammalAdrenal insufficiency: etiology, diagnosis and treatment.Nutritional lipidomics: molecular metabolism, analytics, and diagnosticsHDL-apoA-I exchange: rapid detection and association with atherosclerosisCardiovascular complications of type 1 diabetes: update on the renal link.Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Triglycerides and HDL cholesterol: stars or second leads in diabetes?Tobacco Smoke Exposure Reduces Paraoxonase Activity in a Murine Model.Reduced HDL function in children and young adults with type 1 diabetes.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis.Impact of estimated HDL particle size via the ratio of HDL-C and apoprotein A-I on short-term prognosis of diabetic patients with stable coronary artery disease.Arginine-directed glycation and decreased HDL plasma concentration and functionalityCoronary heart disease risks associated with high levels of HDL cholesterolLow high-density lipoprotein cholesterol: current status and future strategies for management.Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapyAnti-oxidant properties of high-density lipoprotein and atherosclerosisCholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels.Dysfunctional high-density lipoproteinAssociation of lipoprotein subfractions and coronary artery calcium in patient at intermediate cardiovascular risk.Effects of salt intake on blood pressure in banovici coal mine workersRelationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study.High-density lipoprotein cholesterol in diabetes: is higher always better?Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort studyHigh-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese womenArachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African AmericansHigh-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).Ruminant-produced trans-fatty acids raise plasma HDL particle concentrations in intact and ovariectomized female Hartley guinea pigs.Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study.New molecular insights into CETP structure and function: a review.High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol.Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
P2860
Q21132391-EA84F3EF-4EF3-437B-B3A8-2383C8130FD9Q24608464-D93115CC-11C6-459A-9FD2-424BB7DEBF87Q26775420-8E9F4580-0A98-498C-9B9B-819E4D7BC8C0Q26779287-CB53B9B5-F347-4FC7-9F04-2FE7E0D28465Q27000421-10AC0228-D4C8-4A4B-B91F-B601054491CEQ27310980-197026A9-01BA-4A73-9300-D2F4BDE1AB92Q27693268-85DACE2D-CB84-41FC-97D8-54F1D0968975Q28390150-B8854FF7-A7C6-420B-8070-0BDB61414EC4Q28535779-9FA5EE3F-5DCC-46FE-A8E7-415F3CA7092AQ30239971-2B0C4D38-A9C9-4560-8171-41478EB3C1E0Q33590777-C07D10E5-E520-4956-BC55-CE99D3801C99Q33610637-14623F97-22D0-472F-A280-5257B2580280Q33650636-7F44F84A-F7B1-42EB-B710-18B92F4F241FQ33882594-2FFBDA32-1C94-4D4A-A16B-F41B6E3B2A61Q33972551-93B334AD-2A91-4B19-AA47-AA19A18F1CF1Q34037325-F31C3E8C-AAD7-440F-88AF-8CDD2B642687Q34260460-D96355ED-19EC-4E1E-83BB-9674656182AFQ34284245-3AF64498-0FAB-4040-ADFA-E638FA0F0BE1Q34297247-BB8A5C54-8556-4E5D-A6D6-03724BC056D1Q34334846-E7B1CA87-C632-44BD-BB88-2067B9125968Q34417470-2A446DAB-6453-4346-B776-EDC8A0086842Q34440172-1FE561C7-5C76-4AFE-B39F-1918AA61169BQ34635305-57137E70-6B3C-436D-9169-24B693868EC1Q34727869-899EA576-0455-4CE1-9DEF-23C0D79FF882Q34778027-808D04D7-A994-48FD-95ED-9D3BAC56D0C5Q35039152-ECD54782-A653-463E-A620-3492AC17EA96Q35088129-ED7D9A8A-902D-46C0-B89C-78885024691CQ35212898-3396B14E-BA97-4055-ACFA-D1B840B0AA83Q35221749-A6DF0902-C3E6-4876-A5DE-8251B6A582D9Q35302241-0D088F5A-3B72-45FB-A12A-3B249E9978DCQ35602017-EF9425D5-FDFC-44AA-AA55-3BCD05A3155AQ35722425-FDE2024E-E677-42C4-ABD4-C73DA61F5939Q36096325-5A474344-141E-41E0-B2E9-7A5462F48C84Q36139932-347E9293-6D02-454A-9F52-2384815DE3CEQ36160317-E960B52B-B790-4BDE-9477-EAEFB9239431Q36366340-3D2B5C24-A7CA-4C0D-876B-07FFD8352203Q36404574-1024FD5A-BC4E-4FFA-87A5-D3BB9061023AQ36520363-C6951B3F-A804-4DFA-A97E-ABC690A9B3DBQ36607325-B18DCFBD-B2D9-4332-937E-D1FE532F6F33Q36835900-B2B37BD8-DF51-4CE0-9069-C563C2FBFCDD
P2860
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@ast
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@en
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@nl
type
label
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@ast
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@en
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@nl
prefLabel
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@ast
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@en
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@nl
P2093
P921
P1476
High-density lipoprotein chole ...... DEAL and EPIC-Norfolk studies.
@en
P2093
Anders G Olsson
Christina Lindahl
Erik S G Stroes
Ingar Holme
John J P Kastelein
Matti J Tikkanen
Mogens Lytken Larsen
Ole Faergeman
S Matthijs Boekholdt
Terje R Pedersen
P304
P356
10.1016/J.JACC.2007.09.060
P407
P577
2008-02-01T00:00:00Z